L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 7, 2005, Pages 2522-2530

  Tomi, Masatoshi ^a   Mori, Masahiko ^a   Tachikawa, Masanori ^b   Katayama, Kazunori ^a   Terasaki, Tetsuya ^b,c   Hosoya, Ken Ichi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID TRANSPORTER; DEXTRO PHENYLALANINE; GLUTAMINE; LEUCINE; MESSENGER RNA; METHIONINE;

ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; FEMALE; GUINEA PIG; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CULTURE TECHNIQUE; CYTOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PHYSIOLOGY; RETINA BLOOD VESSEL; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-RETINAL BARRIER; CELL CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GUINEA PIGS; IMMUNOBLOTTING; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LEUCINE; MALE; RATS; RATS, WISTAR; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 23244446497     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-1175     Document Type: Article

References (45)

1. Törnquist P, Alm A. Carrier-mediated transport of amino acids through the blood-retinal and the blood-brain barriers. Graefes Arch Clin Exp Ophthalmol. 1986;224:21-25.
2. LaNoue KF, Berkich DA, Conway M, et al. Role of specific aminotransferases in de novo glutamate synthesis and redox shuttling in the retina. J Neurosci Res. 2001;66:914-922.
3. Lieth E, LaNoue KF, Berkich DA, et al. Nitrogen shuttling between neurons and glial cells during glutamate synthesis. J Neurochem. 2001;76:1712-1723.
4. Hosoya K, Tomi M. Advances in the cell biology of transport via the inner blood-retinal barrier: establishment of cell lines and transport functions. Biol Pharm Bull. 2005;28:1-8.
5. Cunha-Vaz JG. The blood-retinal barriers system: basic concepts and clinical evaluation. Exp Eye Res. 2004;78:715-721.
6. Fernandes R, Suzuki K, Kumagai AK. Inner blood-retinal barrier GLUT1 in long-term diabetic rats: an immunogold electron microscopic study. Invest Ophthalmol Vis Sci. 2003;44:3150-3154.
7. Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H. Ultracytochemical localization of the erythrocyte/HepG2-type glucose transporter (GLUT1) in cells of the blood-retinal barrier in the rat. Invest Ophthalmol Vis Sci. 1992;33:377-383.
8. Hjelle JT, Baird-Lambert J, Cardinale G, Specor S, Udenfriend S. Isolated microvessels: the blood-brain barrier in vitro. Proc Natl Acad Sci USA. 1978;75:4544-4548.
9. Kanai Y, Segawa H, Miyamoto K, et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629-23632.
10. Pineda M, Fernandez E, Torrents D, et al. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem. 1999;274:19738-19744.
11. +-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999;274:19745-19751.
12. Kageyama T, Nakamura M, Matsuo A, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 2000;879:115-121.
13. Matsuo H, Tsukada S, Nakata T, et al. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport. 2000;11:3507-3511.
14. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA. 1999;96:12079-12084.
15. Okamoto Y, Sakata M, Ogura K, et al. Expression and regulation of 4F2hc and hLAT1 in human trophoblasts. Am J Physiol. 2002;282:C196-C204.
16. +-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest Ophthalmol Vis Sci. 2003;44:2919-2927.
17. Nakauchi T, Ando A, Ueda-Yamada M, et al. Prevention of ornithine cytotoxicity by nonpolar side chain amino acids in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2003;44:5023-5028.
18. Tomi M, Hosoya K, Takanaga H, Ohtsuki S, Terasaki T. Induction of xCT gene expression and L-cystine transport activity by diethyl maleate at the inner blood-retinal barrier. Invest Ophthalmol Vis Sci. 2002;43:774-779.
19. Hosoya K, Tomi M, Ohtsuki S, et al. Conditionally immortalized retinal capillary endothelial cell lines (TR-iBRB) expressing differentiated endothelial cell functions derived from a transgenic rat. Exp Eye Res. 2001;72:163-172.
20. Nakashima T, Tomi M, Katayama K, et al. Blood-to-retina transport of creatine via creatine transporter (CRT) at the rat inner blood-retinal barrier. J Neurochem. 2004;89:1454-1461.
21. Hosoya K, Minamizono A, Katayama K, Terasaki T, Tomi M. Vitamin C transport in oxidized form across the rat blood-retinal barrier. Invest Ophthalmol Vis Sci. 2004;45:1232-1239.
22. Tomi M, Hosoya K. Application of magnetically isolated rat retinal vascular endothelial cells for the determination of transporter gene expression levels at the inner blood-retinal barrier. J Neurochem. 2004;91:1244-1248.
23. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981;4:879-885.
24. Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J. 2002;21:580-589.
25. -, in the newly developed rat retinal Müller cell line (TR-MUL). Glia. 2003;43:208-217.
26. Ennis SR, Betz AL. Sucrose permeability of the blood-retinal and blood-brain barriers: effects of diabetes, hypertonicity, and iodate. Invest Ophthalmol Vis Sci. 1986;27:1095-1102.
27. Doi M, Yamaoka I, Fukunaga T, Nakayama M. Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes. Biochem Biophys Res Commun. 2003;312:1111-1117.
28. Holecek M, Sprongl L, Tilser I. Metabolism of branched-chain amino acids in starved rats: the role of hepatic tissue. Physiol Res. 2001;50:25-33.
29. Araujo P, Wassermann GF, Tallini K, et al. Reduction of large neutral amino acid levels in plasma and brain of hyperleucinemic rats. Neurochem Int. 2001;38:529-537.
30. Diamond A, Herzberg C. Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria. Brain. 1996;119:523-538.
31. o, + AT) of rBAT. Nat Genet. 1999;23:52-57.
32. Boado RJ, Li JY, Pardridge WM. Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. J Neurochem. 2003;84:1322-1331.
33. Uchino H, Kanai Y, Kim do K, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729-737.
34. Rossier G, Meier C, Bauch C, et al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem. 1999;274:34948-34954.
35. Betz AL, Goldstein GW. Transport of hexoses, potassium and neutral amino acids into capillaries isolated from bovine retina. Exp Eye Res. 1980;30:593-605.
36. +-dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal. Am J Physiol. 2004;287:E622-E629.
37. Takanaga H, Tokuda N, Ohtsuki S, Hosoya K, Terasaki T. ATA2 is predominantly expressed as system A at the blood-brain barrier and acts as brain-to-blood efflux transport for L-proline. Mol Pharmacol. 2002;61:1289-1296.
38. Tetsuka K, Takanaga H, Ohtsuki S, Hosoya K, Terasaki T. The L-isomer-selective transport of aspartic acid is mediated by ASCT2 at the blood-brain barrier. J Neurochem. 2003;87:891-901.
39. Frederick JM, Rayborn ME, Laties AM, Lam DM, Hollyfield JG. Dopaminergic neurons in the human retina. J Comp Neurol. 1982;210:65-79.
40. Chanut E, Nguyen-Legros J, Labarthe B, Trouvin JH, Versaux-Botteri C. Serotonin synthesis and its light-dark variation in the rat retina. J Neurochem. 2002;83:863-869.
41. Pasantes-Morales H, Klethi J, Ledig M, Mandel P. Free amino acids of chicken and rat retina. Brain Res. 1972;41:494-497.
42. Bodis-Wollner I. Visual electrophysiology in Parkinson's disease: PERG, VEP and visual P300. Clin Electroencephalogr. 1997;28:143-147.
43. Bhaskar PA, Vanchilingam S, Bhaskar EA, Devaprabhu A, Ganesan RA. Effect of L-dopa on visual evoked potential in patients with Parkinson's disease. Neurology. 1986;36:1119-1121.
44. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818-825.
45. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33:601-607.